Table 2 Details of adjuvant chemotherapy in the PF group and TPF group
| Â | PF group [n (%), n = 425] | TPF group [n (%), n = 177] | X2/Z | P |
|---|---|---|---|---|
Taxanes | Â | Â | Â | Â |
 Paclitaxel | — | 72 (40.7) | — | — |
 Docetaxel | — | 105 (59.3) | — | — |
Fluoropyrimidines | Â | Â | Â | Â |
 5-Fu | 118 (27.8) | 98 (55.4) | 44.493 | < 0.001 |
 Capecitabine | 182 (42.8) | 37 (20.9) |  |  |
 S1 | 125 (29.4) | 42 (23.7) |  |  |
Platinum | Â | Â | Â | Â |
 Cisplatin | 20 (4.7) | 80 (45.2) | 158.765 | < 0.001 |
 Oxaliplatin | 398 (93.6) | 88 (49.7) |  |  |
 Lobaplatin | 7 (1.6) | 9 (5.1) |  |  |
Time to chemotherapy after surgery (days) [median (IQR)] | 38 (31~47) | 37 (31~47) | −0.167a | 0.867 |
Duration of adjuvant chemotherapy (days) [median (IQR)] | 116 (53~159) | 127 (74~175) | −1.743a | 0.081 |
Cycles of adjuvant chemotherapy [median (IQR)] | 4 (2~6) | 4 (3~6) | −0.711a | 0.477 |